Informa TechTarget Updates on Filing of Annual Report on Form 10-K
NEWTON, Mass.--(BUSINESS WIRE)--Apr 30, 2025--
TechTarget, Inc. (Nasdaq: TTGT) ('Informa TechTarget') (the 'Company'), a leading growth accelerator for the B2B Technology sector, today confirms that it will file its Annual Report on Form 10-K on or before May 30, 2025.
As previously indicated, the Company and auditing firm, PwC US, have discovered that the work required to audit financial statements for a combination of a previously listed US GAAP reporting company and carve-out financials of a UK-listed company reporting under IFRS is both highly technical and time consuming. That work is substantially complete, with the focus of activity on closing out remaining technical accounting matters relating to non-cash items in prior year periods, and the Company's auditors have now outlined the process and associated timetable for final sign-off of the audit. These matters do not affect the current and forward operating and financial performance of the Company, with current performance in line with previous commentary.
The Company therefore plans to file its Annual Report on Form 10-K on or before May 30, 2025, with the intention to align this with the publication of the Company's Q1 Update.
A conference call and webcast with management will be held following the filing, with full details to follow.
The Company's expectation for 2024 revenues and its outlook for 2025 remain as disclosed in its release dated April 15, 2025.
About Informa TechTarget
TechTarget, Inc. (Nasdaq: TTGT), which also refers to itself as Informa TechTarget, informs, influences and connects the world's technology buyers and sellers, helping accelerate growth from R&D to ROI.
With a vast reach of over 220 highly targeted technology-specific websites and over 50 million permissioned first-party audience members, Informa TechTarget has a unique understanding of and insight into the technology market.
Underpinned by those audiences and their data, we offer expert-led, data-driven, and digitally enabled services that have the potential to deliver significant impact and measurable outcomes to our clients:
Informa TechTarget is headquartered in Boston, MA and has offices in 19 global locations. For more information, visit informatechtarget.com and follow us on LinkedIn.
© 2025 TechTarget, Inc. All rights reserved. All trademarks are the property of their respective owners.
View source version on businesswire.com:https://www.businesswire.com/news/home/20250430500021/en/
CONTACT: Investor Inquiries
Mitesh Kotecha
Daniel Noreck
Informa TechTarget
617-431-9200
[email protected] Inquiries
Garrett Mann
Corporate Communications
Informa TechTarget
617-431-9371
[email protected]
KEYWORD: UNITED STATES NORTH AMERICA MASSACHUSETTS
INDUSTRY KEYWORD: INTERNET PUBLISHING FINANCE MARKETING ADVERTISING COMMUNICATIONS PROFESSIONAL SERVICES TECHNOLOGY
SOURCE: TechTarget, Inc.
Copyright Business Wire 2025.
PUB: 04/30/2025 08:36 AM/DISC: 04/30/2025 08:36 AM
http://www.businesswire.com/news/home/20250430500021/en
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Upturn
29 minutes ago
- Business Upturn
Alvotech has carried out a private placement of 7,500,000 SDRs and ordinary shares at a price of SEK 100.00 per SDR and ISK 1320.83 per ordinary share, raising gross proceeds of SEK 750 million
By GlobeNewswire Published on June 5, 2025, 04:55 IST THIS PRESS RELEASE MAY NOT BE DISTRIBUTED, RELEASED, OR PUBLISHED, DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEELAND, RUSSIA, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, SWITZERLAND, RUSSIA, BELARUS, OR ANY OTHER JURISDICTION IN WHICH SUCH ACTIONS, WHOLLY OR IN PART, WOULD BE UNLAWFUL OR DEMAND ADDITIONAL REGISTRATION OR OTHER MEASURES. PLEASE REFER TO 'IMPORTANT INFORMATION' IN THE END OF THIS PRESS RELEASE. Alvotech has carried out a private placement of 7,500,000 SDRs and ordinary shares at a price of SEK 100.00 per SDR and ISK 1320.83 per ordinary share, raising gross proceeds of SEK 750 million REYKJAVIK, ICELAND (June 4, 2025) — Alvotech (NASDAQ: ALVO, the 'Company') has completed a private placement of the equivalent of 7,500,000 shares in Swedish Depository Receipts ('SDRs') and ordinary shares (ALVOIS) at a price of SEK 100.00 per SDR and ISK 1320.83 per ordinary share, with the ISK price being the equivalent of the SEK price (the 'Placement'), for aggregate gross proceeds to the Company of SEK 750 million. The price was determined through an accelerated bookbuilding procedure conducted by DNB Carnegie and Citi as Joint Global Coordinators and Joint Bookrunners, and SEB and ACRO as Joint Bookrunners (together the 'Joint Bookrunners'). The transaction attracted strong interest from institutional investors, with a clear majority allocated to Swedish and other international investors outside of Iceland. The Placement The Board of Directors of Alvotech has, as indicated by the Company through a press release on June 4, 2025, had resolved on a Placement of the equivalent of 7,5000,000 shares. The placement has now been finalized in the sale of 5,833,500 SDRs and 1,666,500 ordinary shares (ALVOIS) at a price of SEK 100.00 per SDR and ISK 1320.83 per ordinary share respectively, with the ISK price being the equivalent of the SEK price, consequently raising gross proceeds of SEK 750 million before deduction of transaction costs. The price in the Placement was determined through an accelerated bookbuilding procedure led by the Joint Bookrunners to Swedish and international institutional investors and therefore, in the assessment of the Board of Directors, reflects prevailing market conditions, as well as the demand for the Company's SDRs on Nasdaq Stockholm and ordinary shares on Nasdaq Iceland. The SDRs and ordinary shares in the Placement will be made available through existing treasury shares held by Alvotech. The transaction attracted strong interest from institutional investors, with a clear majority allocated to Swedish and other international investors outside of Iceland, further signifying the importance of the SDR listing on Nasdaq Stockholm. The net proceeds of the Placement are intended to be used for: (i) upscaling R&D efforts, especially in Sweden after the recently closed acquisition of the R&D operations of Xbrane, thereby further expanding what is already one of the largest biosimilars pipelines globally; (ii) capitalising on selected growth opportunities and strengthen the Company's market position; and (iii) general corporate purposes. Participating investors were required to choose whether they would receive SDRs or ordinary shares listed on Nasdaq Iceland (ALVOIS) prior to the close of the bookbuilding. For investors who requested ordinary shares, payment is to be made in ISK, based on a SEK price per SDR that was converted from SEK to ISK using the mid-rate on the day of bookbuilding close, as published by the Swedish Central Bank (Sw. Sveriges Riksbank ). The Board of Directors has assessed that the Placement will (i) further diversify and strengthen the Company's shareholder base with institutional investors especially in Sweden, where the Company has recently established a trading market for the SDRs, (ii) increase the float of SDRs significantly given the current number of SDRs held by the public on Nasdaq Stockholm, and (iii) enable the Company to act more swiftly on the R&D expansion opportunities. Settlement of the Placement is expected to take place on or about June 10, 2025, for both the SDRs and the ordinary shares (ALVOIS). Lock-up undertakings The Company has undertaken, subject to certain conditions and customary exceptions and provided that the Placement is completed, not to issue, sell, or otherwise transfer or dispose of additional SDRs, ordinary shares, or other securities in the Company without the consent of DNB Carnegie and Citi, acting on behalf of SEB and ACRO, for a period of 180 days following the settlement of the Placement. All members of the executive management and the Board of Directors who hold shares in the Company (directly or indirectly) have undertaken, subject to certain conditions and customary exceptions, not to sell or otherwise transfer or dispose of SDRs, ordinary shares, or other securities in the Company without the consent of DNB Carnegie and Citi, acting on behalf of SEB and ACRO, for a period of 180 days following the settlement of the Placement. Shareholders Aztiq Pharma Partners S.à r.l., Alvogen Lux Holdings S.à r.l. and Celtic Holdings II Limited have not disposed any of their holdings in the Company in connection with the Placement; however, they respectively have undertaken, subject to customary exceptions, not to sell or otherwise dispose of any SDRs, ordinary shares or other securities in the Company without the consent of DNB Carnegie and Citi, acting on behalf of SEB and ACRO, for a period of 90 days following the settlement of the Placement. Advisors DNB Carnegie Investment Bank AB (publ) ('DNB Carnegie') and Citigroup Global Markets Limited ('Citi') acted as Joint Global Coordinators and Joint Bookrunners, and Skandinaviska Enskilda Banken AB (publ) ('SEB') and ACRO Securities HF ('ACRO') acted as Joint Bookrunners in connection with the Placement. Cirio Advokatbyrå AB and Westerberg & Partners acted as legal advisors to the Company as to Swedish law, Arendt & Medernach SA acted as legal advisor to the Company as to Luxembourg law, BBA//Fjeldco acted as legal advisor to the Company as to Icelandic law and Cooley LLP acted as legal advisor to the Company as to U.S. law. Linklaters Advokatbyrå acted as legal advisor to the Joint Bookrunners as to Swedish law and Linklaters LLP acted as legal advisor to the Joint Bookrunners as to US law. For further information, please contact: ALVOTECH INVESTOR RELATIONS AND GLOBAL COMMUNICATIONSBenedikt Stefansson, VP [email protected] This constitutes information that Alvotech is legally obliged to publish under the EU's Market Abuse Regulation. The information was released for publication, through the agency of the contact person above, at the date and time indicated by the dateline of publication. About Alvotech Alvotech is a biotech company, founded by Robert Wessman, focused solely on the development and manufacture of biosimilar medicines for patients worldwide. Alvotech seeks to be a global leader in the biosimilar space by delivering high-quality, cost-effective products and services, enabled by a fully integrated approach and broad in-house capabilities. Two biosimilars, to Humira® (adalimumab) and Stelara® (ustekinumab), are already approved and marketed in multiple global markets. The current development pipeline includes nine disclosed biosimilar candidates aimed at treating autoimmune disorders, eye disorders, osteoporosis, respiratory disease, and cancer. Alvotech has formed a network of strategic commercial partnerships to provide global reach and leverage local expertise in markets that include the United States, Europe, Japan, China, and other Asian countries and large parts of South America, Africa and the Middle East. Alvotech's commercial partners include Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (U.S.), STADA Arzneimittel AG (EU), Fuji Pharma Co., Ltd (Japan), Advanz Pharma (EEA, U.K., Switzerland, Canada, Australia and New Zealand), Dr. Reddy's (EEA, U.K. and U.S.), Biogaran (France), Cipla/Cipla Gulf/Cipla Med Pro (Australia, New Zealand, South Africa/Africa), JAMP Pharma Corporation (Canada), Yangtze River Pharmaceutical (Group) Co., Ltd. (China), DKSH (Taiwan, Hong Kong, Cambodia, Malaysia, Singapore, Indonesia, India, Bangladesh and Pakistan), YAS Holding LLC (Middle East and North Africa), Abdi Ibrahim (Turkey), Kamada Ltd. (Israel), Mega Labs, Stein, Libbs, Tuteur and Saval (Latin America) and Lotus Pharmaceuticals Co., Ltd. (Thailand, Vietnam, Philippines, and South Korea). Each commercial partnership covers a unique set of products and territories. Except as specifically set forth therein, Alvotech disclaims responsibility for the content of periodic filings, disclosures and other reports made available by its partners. For more information, please visit None of the information on the Alvotech website shall be deemed part of this press release. Important information The release, announcement or distribution of this press release may, in certain jurisdictions, be subject to restrictions by law. The recipients of this press release in jurisdictions where this press release has been published or distributed shall inform themselves of and follow such restrictions. The recipient of this press release is responsible for using this press release, and the information contained herein, in accordance with applicable rules in each jurisdiction. This press release is for information purposes only and does not constitute an offer to sell or an offer, or the solicitation of an offer, to acquire or subscribe for SDRs, shares or other securities issued by the Company, neither by the Company or anyone else, in any jurisdiction where such offer or invitation would be illegal prior to registration, exemption from registration or qualification under the securities laws of such jurisdiction. This press release is not a prospectus for the purposes of Regulation (EU) 2017/1129 (the 'Prospectus Regulation') and has not been approved by any regulatory authority in any jurisdiction. The Company has not authorised any offer to the public of SDRs, shares or other securities in any member state of the EEA and no prospectus has been or will be prepared in connection with the Placement. In any EEA Member State, this communication is only addressed to and is only directed at 'qualified investors' in that Member State within the meaning of the Prospectus Regulation. This press release does not constitute or form part of an offer or solicitation to purchase or subscribe for securities in the United States. The SDRs, the ordinary shares underlying the SDRs and the new ordinary shares referred to herein may not be sold in the United States absent registration or an exemption from registration under the US Securities Act of 1933, as amended (the 'Securities Act'), or under the securities laws of any state or other jurisdiction of the United States and, accordingly, may not be offered or sold within the United States absent registration or an applicable exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and in compliance with applicable state securities law. There is no intention to register any securities referred to herein in the United States or to make a public offering of the securities in the United States. The sale of the securities referred to herein in the United States is being made solely to a limited number of 'qualified institutional buyers' as defined in Rule 144A in reliance on an exemption from the registration requirements of the Securities Act. The information in this press release may not be announced, published, copied, reproduced or distributed, directly or indirectly, in whole or in part, within or into Australia, Belarus, Canada, Hong Kong, Japan, New Zeeland, Russia, Switzerland, Singapore, South Africa, South Korea, or in any other jurisdiction where such announcement, publication or distribution of the information would not comply with applicable laws and regulations or where such actions are subject to legal restrictions or would require additional registration or other measures than what is required under Swedish law. Actions taken in violation of this instruction may constitute a crime against applicable securities laws and regulations. In the United Kingdom, this press release and any other materials in relation to the securities described herein is only being distributed to, and is only directed at, and any investment or investment activity to which this document relates is available only to, and will be engaged in only with, 'qualified investors' who are (i) persons having professional experience in matters relating to investments who fall within the definition of 'investment professionals' in Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the 'Order'); or (ii) high net worth entities falling within Article 49(2)(a) to (d) of the Order (all such persons together being referred to as 'relevant persons'). In the United Kingdom, any investment or investment activity to which this communication relates is available only to, and will be engaged in only with, relevant persons. Persons who are not relevant persons should not take any action on the basis of this press release and should not act or rely on it. This announcement does not identify or suggest, or purport to identify or suggest, the risks (direct or indirect) that may be associated with an investment in the new shares. Any investment decision to acquire or subscribe for shares in connection with the Placement must be made on the basis of all publicly available information relating to the Company and the Company's shares. Such information has not been independently verified by the Joint Bookrunners. The Joint Bookrunners are acting for the Company and no one else in connection with the Placement and are not responsible to anyone other than the Company for providing the protections afforded to its clients nor for giving advice in relation to the Placement or any other matter referred to herein. This press release does not constitute a recommendation for any investors' decisions regarding the Placement. Each investor or potential investor should conduct a self-examination, analysis and evaluation of the business and information described in this press release and any publicly available information. The price and value of the securities can decrease as well as increase. Achieved results do not provide guidance for future results. Neither the contents of the Company's website nor any other website accessible through hyperlinks on the Company's website are incorporated into or form part of this press release. Failure to follow these instructions may result in a breach of the Securities Act or applicable laws in other jurisdictions. Alvotech forward-looking statements Certain statements in this communication may be considered 'forward-looking statements' within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements generally relate to future events or the future financial operating performance of Alvotech and may include, for example, the timing of the settlement of the Placement, Alvotech's ability to satisfy the closing conditions and close the Placement, the anticipated use of proceeds from the Placement, Alvotech's future results of operations, financial condition, liquidity, performance, prospects, anticipated growth, strategies and opportunities and the market in which the Company operates. In some cases, you can identify forward-looking statements by terminology such as 'may', 'should', 'expect', 'intend', 'will', 'estimate', 'anticipate', 'believe', 'predict', 'potential', 'aim' or 'continue', or the negatives of these terms or variations of them or similar terminology. Such forward-looking statements are subject to risks, uncertainties, and other factors which could cause actual results to differ materially from those expressed or implied by such forward-looking statements. These forward-looking statements are based upon estimates and assumptions that, while considered reasonable by Alvotech and its management, are inherently uncertain and are inherently subject to risks, variability, and contingencies, many of which are beyond Alvotech's control. Factors that may cause actual results to differ materially from current expectations include, but are not limited to: (1) changes in applicable laws or regulations; (2) the possibility that Alvotech may be adversely affected by economic, business, and/or competitive factors; (3) Alvotech's estimates of expenses and profitability; (4) Alvotech's ability to develop, manufacture and commercialize the products and product candidates in its pipeline; (5) actions of regulatory authorities, which may affect the initiation, timing and progress of clinical studies or future regulatory approvals or marketing authorizations; (6) the ability of Alvotech or its partners to respond to inspection findings and resolve deficiencies to the satisfaction of the regulators; (7) the ability of Alvotech or its partners to enrol and retain patients in clinical studies; (8) the ability of Alvotech or its partners to gain approval from regulators for planned clinical studies, study plans or sites; (9) the ability of Alvotech's partners to conduct, supervise and monitor existing and potential future clinical studies, which may impact development timelines and plans; (10) Alvotech's ability to obtain and maintain regulatory approval or authorizations of its products, including the timing or likelihood of expansion into additional markets or geographies; (11) the success of Alvotech's current and future collaborations, joint ventures, partnerships or licensing arrangements; (12) Alvotech's ability, and that of its commercial partners, to execute their commercialization strategy for approved products; (13) Alvotech's ability to manufacture sufficient commercial supply of its approved products; (14) the outcome of ongoing and future litigation regarding Alvotech's products and product candidates; (15) the impact of worsening macroeconomic conditions, including tariffs on Alvotech's products in the U.S. or other markets, rising inflation and interest rates and general adverse market conditions, including the impact of conflicts in Ukraine, the Middle East and other global geopolitical tension, on the Company's business, financial position, strategy and anticipated milestones; and (16) other risks and uncertainties set forth in the sections entitled 'Risk Factors' and 'Cautionary Note Regarding Forward-Looking Statements' in documents that Alvotech may from time to time file or furnish with the SEC. There may be additional risks that Alvotech does not presently know or that Alvotech currently believes are immaterial that could also cause actual results to differ from those contained in the forward-looking statements. Nothing in this communication should be regarded as a representation by any person that the forward-looking statements set forth herein will be achieved or that any of the contemplated results of such forward-looking statements will be achieved. You should not place undue reliance on forward-looking statements, which speak only as of the date they are made. Alvotech does not undertake any duty to update these forward-looking statements or to inform the recipient of any matters of which it becomes aware of which may affect any matter referred to in this communication. Alvotech expressly disclaims any and all liability for any loss or damage (whether foreseeable or not) suffered or incurred by any person or entity as a result of anything contained or omitted from this communication. The recipient agrees that it shall not seek to sue or otherwise hold Alvotech or any of its directors, officers, employees, affiliates, agents, advisors, or representatives liable in any respect for the provision of this communication, the information contained in this communication, or the omission of any information from this communication. Information to distributors Solely for the purposes of the product governance requirements contained within: (a) EU Directive 2014/65/EU on markets in financial instruments, as amended ('MiFID II'); (b) Articles 9 and 10 of Commission Delegated Directive (EU) 2017/593 supplementing MiFID II; and (c) local implementing measures (together, the 'MiFID II Product Governance Requirements'), and disclaiming all and any liability, whether arising in tort, contract or otherwise, which any 'manufacturer' (for the purposes of the MiFID II Product Governance Requirements) may otherwise have with respect thereto, the Company's shares have been subject to a product approval process, which has determined that such shares are: (i) compatible with an end target market of retail investors and investors who meet the criteria of professional clients and eligible counterparties, each as defined in MiFID II (the 'Positive Target Market'); and (ii) eligible for distribution through all distribution channels as are permitted by MiFID II. Distributors should note that: the price of the shares in the Company may decline and investors could lose all or part of their investment; the shares in the Company offer no guaranteed income and no capital protection; and an investment in the shares in the Company is compatible only with investors who do not need a guaranteed income or capital protection, who (either alone or in conjunction with an appropriate financial or other adviser) are capable of evaluating the merits and risks of such an investment and who have sufficient resources to be able to bear any losses that may result therefrom. Conversely, an investment in the shares of the Company is not suitable for investors who need full capital protection or full repayment of the amount invested, cannot bear any risk, or who require guaranteed or predictable return (the 'Negative Target Market', and together with the Positive Target Market, the 'Target Market Assessment'). The Target Market Assessment is without prejudice to the requirements of any contractual, legal or regulatory selling restrictions in relation to the Placement. For the avoidance of doubt, the Target Market Assessment does not constitute: (a) an assessment of suitability or appropriateness for the purposes of MiFID II; or (b) a recommendation to any investor or group of investors to invest in, or purchase, or take any other action whatsoever with respect to the shares in the Company. Each distributor is responsible for undertaking its own Target Market Assessment in respect of the shares in the Company and determining appropriate distribution channels. Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same. GlobeNewswire provides press release distribution services globally, with substantial operations in North America and Europe.
Business Upturn
29 minutes ago
- Business Upturn
NevGold Adds More Significant Oxide Gold-Antimony Results: 7.04 g/t AuEq Over 15.2 Meters (6.37 g/t Au And 0.15% Antimony) Within 4.14 g/t AuEq Over 29.0 Meters (3.56 g/t Au And 0.13% Antimony), and Expands Gold-Antimony Mineralization Over 400 Meters Along Strike at the Limousine Butte Project, Nevada
Vancouver, British Columbia, June 04, 2025 (GLOBE NEWSWIRE) — NevGold Corp. ('NevGold' or the 'Company') (TSXV:NAU) (OTCQX:NAUFF) (Frankfurt:5E50) is pleased to announce that it has discovered further significant oxide gold-antimony ('Antimony', 'Sb') drill results at its Limousine Butte Project (the 'Project', 'Limo Butte') in Nevada. The Company continues to unlock the substantial gold-antimony potential of the Project, highlighting its promising prospects for further exploration and development in Nevada, one of the world's prolific mining jurisdictions. Key Highlights Some of the highest gold-antimony grades seen to date at Resurrection Ridge including: LIM-46: 7.04 g/t AuEq* over 15.2 meters (6.37 g/t Au and 0.15% Sb), within 4.14 g/t AuEq* over 29.0 meters (3.56 g/t Au and 0.13% Sb LB016: 0.61 g/t AuEq* over 36.6 meters from surface (0.16 g/t Au and 0.10% Sb) extending mineralization over 400 meters along strike and opening up large, undrilled areas of the Project for further expansion; the mineralization footprint now expands over 800 meters at Resurrection Ridge (see Figure 1, Figure 2) within a larger +5 km strike length between Resurrection Ridge and Cadillac Valley (Figure 3) *Gold equivalents ('AuEq') are based on assumed metals prices of US$2,000/oz of gold and US$35,000 per tonne of antimony (~30% discount to current spot prices), and assumed metals recoveries of 85% for gold and 70% for antimony. including: Drillholes at Resurrection Ridge are drilled with spacing showing strong potential to advance the Project to an initial gold-antimony Mineral Resource Estimate ('MRE') (see Figure 1) Over 20 holes have been released to date; the Company has more than 30 holes with pending results from Resurrection Ridge and Cadillac Valley Metallurgical testwork program has commenced with over 100 kg bulk sample from the Project and NevGold core drilling; results are expected over the coming weeks Resurrection Ridge and Cadillac Valley oxide gold-antimony mineralization demonstrates the significant oxide gold-antimony potential across a large, open mineralized footprint (Figure 1, Figure 4) Significant antimony (Sb) upside: historical drilling had an upper detection limit of 1% Sb but drill intervals exceeded the limit ; these samples are currently being re-assayed at American Assay Lab in Reno, Nevada NevGold will continue re-evaluating historical drilling from the Project, focusing on both oxide gold and antimony Limo Butte Planned 2025 Activities / Status Update NevGold will continue its active exploration program at Limo Butte including: Evaluate the historical geological database with focus on gold and antimony (in progress); Re-analyze historical drilling with focus on gold and antimony (in progress); Metallurgical testwork (in progress); Drill test gold-antimony targets (in planning phase). Figure 1 – Limousine Butte Gold-Antimony Project with selected gold-antimony drillhole results. To view image please click here Figure 2 – Limousine Butte Gold-Antimony Project cross-section with selected gold-antimony drillhole results. Thin colored discs show Antimony (Sb ppm) in drilling, and wide colored discs show Gold (Au ppm) in drilling. To view image please click here Figure 3 – Limousine Butte Gold-Antimony Project with selected gold-antimony drillhole results at Resurrection Ridge and Cadillac Valley. The total strike length between Resurrection Ridge and Cadillac Valley is +5km. To view image please click here NevGold CEO, Brandon Bonifacio, comments: 'These results have some of the highest oxide gold-antimony grades that we have seen to date at Limo Butte. We have also started to expand the mineralization footprint at Resurrection Ridge, with over 800 meters defined, and we still have over 30 holes to release prior to commencing our 2025 drill program. We are continuing to see exceptional oxide gold-antimony results across a large area at the Project, and we will remain focused on adding to the mineralization footprint and filling in some of the gaps in the gold-antimony geological database, with the goal of rapidly advancing Limo Butte to an initial gold-antimony Mineral Resource Estimate ('MRE') in 2025. Our metallurgical testwork program continues to advance to outline the optimal flowsheet to recover the gold and antimony, and we are expecting results over the coming weeks. The environment is optimal to continue to advance and unlock the gold-antimony potential at Limo Butte as there is a clear commitment from the United States to advance high-quality, domestic, mineral projects.' Historical and Re-Assayed Drill Results Hole ID Length, m* g/t Au % Sb g/t AuEq** From, m To, m Resurrection Ridge LIM-46 29.0 3.56 0.13% 4.14 120.4 149.4 including 15.2 6.37 0.15% 7.04 126.5 141.7 LB016 36.6 0.16 0.10% 0.61 0 36.6 LB018*** 74.7 0.45 0.23% 1.47 36.6 111.3 including 18.2 0.92 0.60% 3.59 73.2 91.4 also including 6.0 0.31 0.96% 4.61 73.2 79.2 LB030*** 12.2 0.58 0.32% 2.03 170.7 182.9 LB002*** 25.0 0.07 0.13% 0.67 0.0 25.0 LB21-002*** 64.0 0.72 0.33% 2.19 48.2 112.2 including 24.1 1.47 0.60% 4.17 50.6 74.7 also including 4.5 1.43 2.10% 10.86 67.4 71.9 LB21-003*** 20.1 1.91 0.17% 2.68 62.5 82.6 LB024*** 61.0 0.26 0.18% 1.07 79.3 140.2 LB023*** 67.1 1.30 0.18% 2.11 24.4 91.5 including 30.5 2.79 0.33% 4.29 30.5 61.0 also including 16.8 5.05 0.46% 7.12 42.7 59.4 LB029*** 79.3 0.53 0.14% 1.16 122.0 201.2 including 18.3 0.52 0.30% 1.86 128.0 146.3 LB013*** 49.7 0.15 0.26% 1.29 30.8 80.5 LB21-005*** 79.2 0.22 0.08% 0.56 64.5 143.7 including 8.6 0.59 0.46% 2.66 65.5 74.1 LB006*** 86.9 1.11 0.30% 2.46 36.6 123.4 including 12.8 1.83 0.87% 5.75 79.2 92.0 also including 6.7 2.29 +1%**** 6.77 85.3 92.0 LB001*** 63.9 0.21 0.33% 1.69 13.1 77.0 including 17.7 0.38 0.83% 4.10 55.2 72.8 also including 6.4 0.16 +1%**** 4.64 55.2 61.6 LB003*** 22.3 2.26 0.32% 3.69 67.1 89.3 including 7.9 5.97 0.57% 8.55 81.4 89.3 LB004*** 110.4 0.19 0.12% 0.73 0.0 110.4 including 36.6 0.24 0.21% 1.16 6.7 43.3 LIM-40*** 54.9 1.20 0.64% 4.07 18.3 73.2 including 12.2 2.12 +1%**** 6.60 48.8 61.0 LIM-45*** 36.6 1.23 0.40% 3.02 24.4 61.0 including 12.2 0.35 +1%**** 4.83 36.6 48.8 LIM-48*** 61.0 0.77 0.41% 2.61 24.4 85.4 including 24.4 0.37 0.77% 3.82 48.8 73.2 Hole ID Length, m* g/t Au % Sb g/t AuEq** From, m To, m Cadillac Valley LB22-007*** 169.2 0.89 0.18% 1.70 213.5 382.7 including 54.4 2.26 0.13% 2.85 213.5 267.9 also including 3.10 0.76 2.76% 13.15 259.2 267.9 LB22-006*** 124.7 0.84 0.11% 1.34 127.4 252.1 including 24.3 1.32 0.20% 2.23 160.6 184.9 LB22-019*** 28.9 1.09 0.04% 1.27 170.7 199.6 LB054*** 12.2 0.42 0.08% 0.79 12.2 24.4 *Downhole thickness reported; true width varies depending on drill hole dip and is approximately 70% to 90% of downhole thickness. **The gold equivalents ('AuEq') are based on assumed metals prices of US$2,000/oz of gold and US$35,000 per tonne of antimony (~30% discount to current spot prices), and assumed metals recoveries of 85% for gold and 70% for antimony. ***Selected drillholes released in previous News Releases on February 27, 2025, March 26, 2025, April 10, 2025, April 24, 2025, May 13, 2025, and June 3, 2025. **** Historical drilling had an upper detection limit of 1% Sb but many drill intervals exceeded the limit. Limo Butte Geology & Antimony Summary A review of historical geochemical and drilling data at the Limousine Butte Project has identified multiple areas with strong gold-antimony potential. These zones correlate closely with outcrops of the Devonian Pilot Shale, the primary host rock for Carlin-type gold mineralization in the area. Positive gold grade at Limousine Butte is typically associated with silicification and the formation of jasperoid breccias within the Pilot Shale, an alteration feature also observed in the positive antimony results. Through the Project data review, the Company uncovered reports detailing two small-scale historic mining operations at the Nevada Antimony Mine and Lage Antimony Prospect within the Limo Butte Project boundary. The Nevada Antimony Mine featured two prospect pits that extracted stibnite (formula: Sb 2 S 3 ) from a hydrothermal breccia. The Lage Antimony Prospect reported historical unverified sampling results with up to 14.46% Antimony with additional prospect pits extracting antimony. Historical geochemical rock chip sampling within the past-producing Golden Butte pit from a Brigham Young University ('BYU') Thesis study produced numerous results that exceeded 1% antimony in jasperoid breccias (see Figure 1). Several results were greater than 5% antimony, including a sample of 9.6% antimony with visible stibnite and stibiconite. BYU Thesis Report NevGold VP Exploration, Greg French, comments: 'These results are some of the strongest gold-antimony grades seen at the Project. It is also encouraging to see the mineralization extend along strike to the south where there is little antimony assay drill data, and to the north where there is minimal historical drilling. With our robust understanding of the structures and key mineralization host rocks, these areas will be a focus of our 2025 drilling as we look to expand the oxide gold-antimony mineralization footprint along strike. We are excited to commence our 2025 drill program shortly which will be focused on strengthening our current gold-antimony geological database, along with making new gold-antimony discoveries.' Figure 4 – Limousine Butte Project with historical antimony in rock chips and soils. The total strike length between Resurrection Ridge and Cadillac Valley is +5km. To view image please click here US Executive Order – Announced March 20, 2025 The Company is pleased to report the recent, sweeping Executive Order to strengthen American mineral production and reduce U.S. reliance on foreign nations for its mineral supply. Antimony (Sb) has been identified as an important 'Critical Mineral' in the United States essential for national security, clean energy, and technology applications, yet no domestically mined supply currently exists. The Executive Order invokes the use of the Defense Production Act as part of a broad United States ('US') Government effort to expand domestic minerals production on national security grounds. As it relates to project permitting, the Order states that it will 'identify priority projects that can be immediately approved or for which permits can be immediately issued, and take all necessary or appropriate actions…to expedite and issue the relevant permits or approvals.' Furthermore, the Order includes provisions to accelerate access to private and public capital for domestic projects, including the creation of a 'dedicated mineral and mineral production fund for domestic investments' under the Development Finance Corporation ('DFC'). This decisive action by the US Government highlights the urgent need to expand domestic minerals output to support supply chain security in the United States. This important Order will help revitalize domestic mineral production by improving the permitting process and providing financial support to qualifying domestic projects. Importance of Antimony Antimony is considered a 'Critical Mineral' by the United States based on the U.S. Geological Survey's 2022 list (U.S.G.S. (2022)). 'Critical Minerals' are metals and non-metals essential to the economy and national security. Antimony is utilized in all manners of military applications, including the manufacturing of armor piercing bullets, night vision goggles, infrared sensors, precision optics, laser sighting, explosive formulations, hardened lead for bullets and shrapnel, ammunition primers, tracer ammunition, nuclear weapons and production, tritium production, flares, military clothing, and communication equipment. Other uses include technology (semi-conductors, circuit boards, electric switches, fluorescent lighting, high quality clear glass and lithium-ion batteries) and clean-energy storage. Globally, approximately 90% of the world's current antimony supply is produced by China, Russia, and Tajikistan. Beginning on September 15, 2024, China, which is responsible for nearly half of all global mined antimony output and dominates global refinement and processing, announced that it will restrict antimony exports. In December-2024, China explicitly restricted antimony exports to the United States citing its dual military and civilian uses, which further exacerbated global supply chain concerns. (Lv, A. and Munroe, T. (2024)) The U.S. Department of Defense ('DOD') has designated antimony as a 'Critical Mineral' due to its importance in national security, and governments are now prioritizing domestic production to mitigate supply chain disruptions. Projects exploring antimony sources in North America play a key role in addressing these challenges. Perpetua Resources Corp. ('Perpetua', NASDAQ:PPTA, TSX:PPTA) has the most advanced domestic gold-antimony project in the United States. Perpetua's project, known as Stibnite, is located in Idaho approximately 130 km northeast of NevGold's Nutmeg Mountain and Zeus projects. Positive advancements at Stibnite including the technical development and permitting has led to US$75 million in Department of Defense ('DOD') awards, and over $1.8 billion in indicative financing from the Export Import Bank of the United States ('US EXIM') (see Perpetua Resources News Release from April 8, 2024) (Perpetua Resources. (2025)) Drillhole Orientation Details Hole ID Target Zone Easting Northing Elevation (m) Length (m) Azimuth Dip LIM-46 RR 667271 4417374 2187 182.9 0 -90 LIM016 RR 666518 4417359 2073 91 0 -90 LB018 RR 666993 4417308 2132 152.4 0 -90 LB030 RR 667143 4417273 2174 193.5 0 -60 LB002 RR 667177 4417244 2192 182.9 82 -50 LB21-002 RR 666979 4417343 2117 151.8 0 90 LB21-003 RR 667061 4417417 2129 183.5 0 90 LB024 RR 667217 4417423 2159 189 70 -80 LB023 RR 667143 4417273 2174 187 70 -60 LB029 RR 667128 4417307 2162 237.7 0 -90 LB013 RR 667142 4417273 2177 164.7 90 -50 LB21-005 RR 667279 4417487 2179 253.8 0 -90 LB006 RR 667030 4417384 2125 152.7 0 -90 LB001 RR 667036 4417384 2125 77 0 -90 LB003 RR 667134 4417528 2133 129.4 0 -90 LB004 RR 667313 4417277 2239 198.7 270 -50 LIM-40 RR 667018 4417409 2124 289.6 0 -90 LIM-45 RR 666929 4417389 2103 179.8 0 -90 LIM-48 RR 666927 4417374 2105 286.5 0 -90 LB22-007 CV 665211 4415453 2031 403.5 254 -86 LB22-006 CV 664692 4414921 2042 379.8 144 -77 LB22-019 CV 664433 4414318 2096 335.3 116 -66 LB054 CV 665323 4415090 2059 157.0 0 -90 Figure 5 – Limousine Butte Land Holdings and District Exploration Activity To view image please click here Engagement of Marketing Consultants The Company has retained Machai Capital Inc. ('Machai Capital'), based in Vancouver, Canada, to provide marketing services including advertising, press release distribution, native advertising of editorial, and additional services as may be determined. Machai Capital will utilize its expertise in branding, content and data optimization, search engine optimization, search engine marketing, lead generation, digital marketing, social media marketing, email marketing, and brand marketing to enhance the Company's marketing campaigns and increase awareness of the Company. The program is budgeted for C$350,000 over a two-month term starting on June 1, 2025. Machai Capital and its principals have an arm's length relationship with the Company. Machai Capital currently owns 50,000 shares of the Company. The Company has also retained Equedia Network Corporation ('Equedia Network'), based in Vancouver, Canada, to provide advertising, press release distribution, native advertising of editorial, and additional services as may be determined. The program will utilize non-generic marketing channels to provide the Company exposure to fresh investment audiences. The advertising program is budgeted for C$150,000 over a six-month term starting on June 1, 2025. Equedia Network and its principals have an arm's length relationship with the Company. Additionally, NevGold announces that it has entered into a digital marketing services agreement with Altura Media Co Inc. ('Altura'), who is based in British Columbia, for an initial three-month period expected to commence on June 9, 2025. Under the agreement, Altura will provide a comprehensive suite of services, including digital advertising, media creation, social media marketing and shareholder communications. In consideration of its services, the Company will pay Altura Media a fee of up to C$150,000. Altura and its principals have an arm's length relationship with the Company. ON BEHALF OF THE BOARD 'Signed' Brandon Bonifacio, President & CEO For further information, please contact Brandon Bonifacio at [email protected], call 604-337-4997, or visit our website at . Historical Data Validation NevGold QA/QC protocols are followed on the Project and include insertion of duplicate, blank and standard samples in all drill holes. A 30g gold fire assay and multi-elemental analysis ICP-OES method was completed by ISO 17025 certified American Assay Labs, Reno. The Company's Qualified Person ('QP'), Greg French, Vice President, Exploration has completed a review of the historical data in this press release. The historic data collection chain of custody procedures and analytical results by previous operators appear adequate and were completed to industry standard practices. For the Newmont and US Gold data a 30g gold fire assay and multi-elemental analysis ICP-OES method MS-41 was completed by ISO 17025 certified ALS Chemex, Reno or Elko Nevada. Geochemical ICP (5g) analysis for the Wilson, Christianson and Tingey report was completed by Geochemical Services Inc. and the XRF analyses (glass disk or pellets) by Brigham Young University. Technical information contained in this news release has been reviewed and approved by Greg French, CPG, the Company's Vice President, Exploration, who is NevGold's Qualified Person under National Instrument 43-101 and responsible for technical matters of this release. About the Company NevGold is an exploration and development company targeting large-scale mineral systems in the proven districts of Nevada and Idaho. NevGold owns a 100% interest in the Limousine Butte and Cedar Wash gold projects in Nevada, and the Nutmeg Mountain gold project and Zeus copper project in Idaho. Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. Cautionary Note Regarding Forward Looking Statements This news release contains forward-looking statements that are based on the Company's current expectations and estimates. Forward-looking statements are frequently characterized by words such as 'plan', 'expect', 'project', 'intend', 'believe', 'anticipate', 'estimate', 'suggest', 'indicate' and other similar words or statements that certain events or conditions 'may' or 'will' occur. Forward-looking statements include, but are not limited to, the proposed work programs at Limousine Butte, and the exploration potential at Limousine Butte. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that could cause actual events or results to differ materially from estimated or anticipated events or results implied or expressed in such forward-looking statements. Such risks include, but are not limited to, general economic, market and business conditions, and the ability to obtain all necessary regulatory approvals. There is some risk that the forward-looking statements will not prove to be accurate, that the management's assumptions may not be correct or that actual results may differ materially from such forward-looking statements. Accordingly, readers should not place undue reliance on the forward-looking statements. Any forward-looking statement speaks only as of the date on which it is made and, except as may be required by applicable securities laws, the Company disclaims any intent or obligation to update any forward-looking statement, whether as a result of new information, future events or results or otherwise. Forward-looking statements are not guarantees of future performance and accordingly undue reliance should not be put on such statements due to the inherent uncertainty therein. References Blackmon, D. (2021) Antimony: The Most Important Mineral You Never Heard Of. Article Prepared by Forbes. Kurtenbach, E. (2024) China Bans Exports to US of Gallium, Germanium, Antimony in response to Chip Sanctions. Article Prepared by AP News. Lv, A. and Munroe, T. (2024) China Bans Export of Critical Minerals to US as Trade Tensions Escalate. Article Prepared by Reuters. Lv, A. and Jackson, L. (2025) China's Curbs on Exports of Strategic Minerals. Article Prepared by Reuters. Perpetua Resources. (2025) Antimony Summary. Articles and Videos Prepared by Perpetua Resources. Sangine, E. (2022) U.S. Geological Survey, Mineral Commodity Summaries, January 2023. Antimony Summary Report prepared by U.S.G.S U.S.G.S. (2022) U.S. Geological Survey Releases 2022 List of Critical Minerals. Reported Prepared by U.S.G.S Wilson, D.,J., Christiansen, E., H., and Tingey, D., G., 1994, Geology and Geochemistry of the Golden Butte Mine- A Small Carlin- Type Gold Deposit in Eastern Nevada: Brigham Young University Geology Studies, v.40, P.185-211. BYU V.40 P.185-211. Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same.
Business Upturn
29 minutes ago
- Business Upturn
LGI Homes, Inc. Reports May 2025 Home Closings
By GlobeNewswire Published on June 5, 2025, 03:04 IST THE WOODLANDS, Texas, June 04, 2025 (GLOBE NEWSWIRE) — LGI Homes, Inc. (NASDAQ: LGIH) today announced it closed 416 homes in May 2025. As of May 31, 2025, the Company had 145 active selling communities. About LGI Homes, Inc. Headquartered in The Woodlands, Texas, LGI Homes, Inc. is a pioneer in the homebuilding industry, successfully applying an innovative and systematic approach to the design, construction and sale of homes across 36 markets in 21 states. As one of America's fastest growing companies, LGI Homes has closed over 75,000 homes since its founding in 2003 and has delivered profitable financial results every year. Nationally recognized for its quality construction and exceptional customer service, LGI Homes was named to Newsweek's list of the World's Most Trustworthy Companies. LGI Homes' commitment to excellence extends to its more than 1,000 employees, earning the Company numerous workplace awards at the local, state, and national level, including the Top Workplaces USA 2025 Award. For more information about LGI Homes and its unique operating model focused on making the dream of homeownership a reality for families across the nation, please visit the Company's website at CONTACT:Joshua D. FattorExecutive Vice President, Investor Relations and Capital Markets(281) 210-2586 [email protected] Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same.
